Abstract
Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are inflammatory diseases that typically affect white individuals >50 years. Women are affected ∼2–3 times more often than men. PMR and GCA occur together more frequently than expected by chance. The main symptoms of PMR are pain and stiffness in the shoulders, and often in the neck and pelvic girdle. Imaging studies reveal inflammation of joints and bursae of the affected areas. GCA is a large-vessel and medium-vessel arteritis predominantly involving the branches of the aortic arch. The typical clinical manifestations of GCA are new headache, jaw claudication and visual loss. PMR and GCA usually remit within 6 months to 2 years from disease onset. Some patients, however, have a relapsing course and might require long-standing treatment. Diagnosis of PMR and GCA is based on clinical features and elevated levels of inflammatory markers. Temporal artery biopsy remains the gold standard to support the diagnosis of GCA; imaging studies are useful to delineate large-vessel involvement in GCA. Glucocorticoids remain the cornerstone of treatment of both PMR and GCA, but patients with GCA require higher doses. Synthetic immunosuppressive drugs also have a role in disease management, whereas the role of biologic agents is currently unclear.
Key Points
-
Giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) are linked disorders that predominantly affect elderly white individuals
-
The diagnosis of GCA and PMR is made on the basis of characteristic clinical features and elevated inflammatory markers, but temporal artery biopsy remains the diagnostic gold standard for GCA
-
Early diagnosis is necessary to prevent ischaemic events in GCA; patients with GCA who suffer an ischaemic event are at high risk of developing another attack unless immediately treated
-
Imaging studies are required to diagnose and monitor GCA with large-vessel involvement
-
Glucocorticoids remain the mainstay of treatment for PMR and GCA
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Salvarani, C., Cantini, F., Boiardi, L. & Hunder, G. G. Polymyalgia rheumatica and giant-cell arteritis. N. Engl. J. Med. 347, 261–271 (2002).
Gonzalez-Gay, M. A. et al. Epidemiology of giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum. 61, 1454–1461 (2009).
Smith, C. A., Fidler, W. J. & Pinals, R. S. The epidemiology of giant cell arteritis. Report of a ten-year study in Shelby County, Tennessee. Arthritis Rheum 26, 1214–1219 (1983).
Pereira, L. S. et al. Giant cell arteritis in Asians: a comparative study. Br. J. Ophthalmol. 95, 214–216 (2011).
Salvarani, C., Cantini, F. & Hunder, G. G. Polymyalgia rheumatica and giant-cell arteritis. Lancet 372, 234–245 (2008).
Pipitone, N., Boiardi, L., Bajocchi, G. & Salvarani, C. Long-term outcome of giant cell arteritis. Clin. Exp. Rheumatol. 24, S65–S70 (2006).
Gran, J. T., Myklebust, G., Wilsgaard, T. & Jacobsen, B. K. Survival in polymyalgia rheumatica and temporal arteritis: a study of 398 cases and matched population controls. Rheumatology (Oxford) 40, 1238–1242 (2001).
Nuenninghoff, D. M., Hunder, G. G., Christianson, T. J., McClelland, R. L. & Matteson, E. L. Mortality of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years. Arthritis Rheum. 48, 3532–3537 (2003).
Hunder, G. G. et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum. 33, 1122–1128 (1990).
Karahaliou, M. et al. Colour duplex sonography of temporal arteries before decision for biopsy: a prospective study in 55 patients with suspected giant cell arteritis. Arthritis Res. Ther. 8, R116 (2006).
Dasgupta, B. et al. 2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Ann. Rheum Dis. 71, 484–492 (2012).
Salvarani, C., Gabriel, S. E., O'Fallon, W. M. & Hunder, G. G. The incidence of giant cell arteritis in Olmsted County, Minnesota: apparent fluctuations in a cyclic pattern. Ann. Intern. Med. 123, 192–194 (1995).
Weyand, C. M. et al. Vascular dendritic cells in giant cell arteritis. Ann. NY Acad. Sci. 1062, 195–208 (2005).
Pipitone, N. & Salvarani, C. The role of infectious agents in the pathogenesis of vasculitis. Best Pract. Res. Clin. Rheumatol. 22, 897–911 (2008).
Gonzalez-Gay, M. A., Garcia-Porrua, C. & Ollier, W. E. Polymyalgia rheumatica and biopsy-proven giant cell arteritis exhibit different HLA-DRB1* associations. J. Rheumatol. 30, 2729 (2003).
Gonzalez-Gay, M. A., Amoli, M. M., Garcia-Porrua, C. & Ollier, W. E. Genetic markers of disease susceptibility and severity in giant cell arteritis and polymyalgia rheumatica. Semin. Arthritis Rheum. 33, 38–48 (2003).
Gonzalez-Gay, M. A. et al. IL-6 promoter polymorphism at position -174 modulates the phenotypic expression of polymyalgia rheumatica in biopsy-proven giant cell arteritis. Clin. Exp. Rheumatol. 20, 179–184 (2002).
Salvarani, C. et al. Interleukin-6 promoter polymorphism at position −174 in giant cell arteritis. J. Rheumatol. 32, 2173–2177 (2005).
Gonzalez-Gay, M. A. et al. Contribution of MHC class I region to genetic susceptibility for giant cell arteritis. Rheumatology (Oxford) 46, 431–434 (2007).
Enjuanes, A. et al. Association of NOS2 and potential effect of VEGF, IL6, CCL2 and IL1RN polymorphisms and haplotypes on susceptibility to GCA—a simultaneous study of 130 potentially functional SNPs in 14 candidate genes. Rheumatology (Oxford) 51, 841–851 (2012).
Salvarani, C. et al. PlA1/A2 polymorphism of the platelet glycoprotein receptor IIIA and risk of cranial ischemic complications in giant cell arteritis. Arthritis Rheum. 56, 3502–3508 (2007).
Esteban, M. J. et al. Small-vessel vasculitis surrounding a spared temporal artery: clinical and pathological findings in a series of twenty-eight patients. Arthritis Rheum. 44, 1387–1395 (2001).
Restuccia, G. et al. Small-vessel vasculitis surrounding an uninflamed temporal artery and isolated vasa vasorum vasculitis of the temporal artery: two subsets of giant cell arteritis. Arthritis Rheum. 64, 549–556 (2012).
Makkuni, D. et al. Is intimal hyperplasia a marker of neuro-ophthalmic complications of giant cell arteritis? Rheumatology (Oxford) 47, 488–490 (2008).
Han, J. W. et al. Vessel wall-embedded dendritic cells induce T-cell autoreactivity and initiate vascular inflammation. Circ. Res. 102, 546–553 (2008).
Weyand, C. M. & Goronzy, J. J. Arterial wall injury in giant cell arteritis. Arthritis Rheum. 42, 844–853 (1999).
Pryshchep, O., Ma-Krupa, W., Younge, B. R., Goronzy, J. J. & Weyand, C. M. Vessel-specific Toll-like receptor profiles in human medium and large arteries. Circulation 118, 1276–1284 (2008).
Deng, J., Younge, B. R., Olshen, R. A., Goronzy, J. J. & Weyand, C. M. TH17 and TH1 T-cell responses in giant cell arteritis. Circulation 121, 906–915 (2010).
Ciccia, F. et al. Expression of interleukin-32 in the inflamed arteries of patients with giant cell arteritis. Arthritis Rheum 63, 2097–2104 (2011).
Terrier, B. et al. IL-21 modulates TH1 and TH17 responses in giant cell arteritis. Arthritis Rheum. 64, 2001–2011 (2012).
Visvanathan, S. et al. Tissue and serum markers of inflammation during the follow-up of patients with giant-cell arteritis--a prospective longitudinal study. Rheumatology (Oxford) 50, 2061–2070 (2011).
Kaiser, M., Weyand, C. M., Bjornsson, J. & Goronzy, J. J. Platelet-derived growth factor, intimal hyperplasia, and ischemic complications in giant cell arteritis. Arthritis Rheum. 41, 623–633 (1998).
Lozano, E., Segarra, M., Garcia-Martinez, A., Hernandez-Rodriguez, J. & Cid, M. C. Imatinib mesylate inhibits in vitro and ex vivo biological responses related to vascular occlusion in giant cell arteritis. Ann. Rheum Dis. 67, 1581–1588 (2008).
Kaiser, M., Younge, B., Bjornsson, J., Goronzy, J. J. & Weyand, C. M. Formation of new vasa vasorum in vasculitis. Production of angiogenic cytokines by multinucleated giant cells. Am. J. Pathol. 155, 765–774 (1999).
Wagner, A. D., Goronzy, J. J. & Weyand, C. M. Functional profile of tissue-infiltrating and circulating CD68+ cells in giant cell arteritis. Evidence for two components of the disease. J. Clin. Invest 94, 1134–1140 (1994).
Hernandez-Rodriguez, J. et al. Tissue production of pro-inflammatory cytokines (IL-1β, TNF-α and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis. Rheumatology (Oxford) 43, 294–301 (2004).
Field, M., Cook, A. & Gallagher, G. Immuno-localisation of tumour necrosis factor and its receptors in temporal arteritis. Rheumatol. Int. 17, 113–118 (1997).
Hernandez-Rodriguez, J. et al. Elevated production of interleukin-6 is associated with a lower incidence of disease-related ischemic events in patients with giant-cell arteritis: angiogenic activity of interleukin-6 as a potential protective mechanism. Circulation 107, 2428–2434 (2003).
Segarra, M. et al. Gelatinase expression and proteolytic activity in giant-cell arteritis. Ann. Rheum. Dis. 66, 1429–1435 (2007).
Rodriguez-Pla, A. et al. Metalloproteinase-2 and -9 in giant cell arteritis: involvement in vascular remodeling. Circulation 112, 264–269 (2005).
Machado, E. B. et al. A population-based case–control study of temporal arteritis: evidence for an association between temporal arteritis and degenerative vascular disease? Int. J. Epidemiol. 18, 836–841 (1989).
Duhaut, P. et al. Anticardiolipin antibodies and giant cell arteritis: a prospective, multicenter case-control study. Groupe de Recherche sur l'Arterite a Cellules Geantes. Arthritis Rheum. 41, 701–709 (1998).
Gonzalez-Gay, M. A. et al. Influence of traditional risk factors of atherosclerosis in the development of severe ischemic complications in giant cell arteritis. Medicine (Baltimore) 83, 342–347 (2004).
Weyand, C. M., Hicok, K. C., Hunder, G. G. & Goronzy, J. J. Tissue cytokine patterns in patients with polymyalgia rheumatica and giant cell arteritis. Ann. Intern. Med. 121, 484–491 (1994).
Kreiner, F., Langberg, H. & Galbo, H. Increased muscle interstitial levels of inflammatory cytokines in polymyalgia rheumatica. Arthritis Rheum. 62, 3768–3775 (2010).
Kreiner, F. & Galbo, H. Elevated muscle interstitial levels of pain-inducing substances in symptomatic muscles in patients with polymyalgia rheumatica. Pain 152, 1127–1132 (2011).
Paraskevas, K. I., Boumpas, D. T., Vrentzos, G. E. & Mikhailidis, D. P. Oral and ocular/orbital manifestations of temporal arteritis: a disease with deceptive clinical symptoms and devastating consequences. Clin. Rheumatol. 26, 1044–1048 (2007).
Hayreh, S. S., Podhajsky, P. A. & Zimmerman, B. Ocular manifestations of giant cell arteritis. Am. J. Ophthalmol. 125, 509–520 (1998).
Salvarani, C. et al. Risk factors for severe cranial ischaemic events in an Italian population-based cohort of patients with giant cell arteritis. Rheumatology (Oxford) 48, 250–253 (2009).
Hernandez-Rodriguez, J. et al. A strong initial systemic inflammatory response is associated with higher corticosteroid requirements and longer duration of therapy in patients with giant-cell arteritis. Arthritis Rheum. 47, 29–35 (2002).
Salvarani, C. et al. Risk factors for visual loss in an Italian population-based cohort of patients with giant cell arteritis. Arthritis Rheum. 53, 293–297 (2005).
Gonzalez-Gay, M. A. et al. Permanent visual loss and cerebrovascular accidents in giant cell arteritis: predictors and response to treatment. Arthritis Rheum. 41, 1497–1504 (1998).
Ezeonyeji, A. N., Borg, F. A. & Dasgupta, B. Delays in recognition and management of giant cell arteritis: results from a retrospective audit. Clin. Rheumatol. 30, 259–262 (2011).
Calamia, K. T. & Hunder, G. G. Giant cell arteritis (temporal arteritis) presenting as fever of undetermined origin. Arthritis Rheum. 24, 1414–1418 (1981).
Olopade, C. O., Sekosan, M. & Schraufnagel, D. E. Giant cell arteritis manifesting as chronic cough and fever of unknown origin. Mayo Clin. Proc. 72, 1048–1050 (1997).
Brack, A., Martinez-Taboada, V., Stanson, A., Goronzy, J. J. & Weyand, C. M. Disease pattern in cranial and large-vessel giant cell arteritis. Arthritis Rheum. 42, 311–317 (1999).
Nuenninghoff, D. M., Hunder, G. G., Christianson, T. J., McClelland, R. L. & Matteson, E. L. Incidence and predictors of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years. Arthritis Rheum. 48, 3522–3531 (2003).
Bongartz, T. & Matteson, E. L. Large-vessel involvement in giant cell arteritis. Curr. Opin. Rheumatol. 18, 10–17 (2006).
Blockmans, D. et al. Relationship between fluorodeoxyglucose uptake in the large vessels and late aortic diameter in giant cell arteritis. Rheumatology (Oxford) 47, 1179–1184 (2008).
Garcia-Martinez, A. et al. Development of aortic aneurysm/dilatation during the followup of patients with giant cell arteritis: a cross-sectional screening of fifty-four prospectively followed patients. Arthritis Rheum. 59, 422–430 (2008).
Stone, J. H. Vasculitis: a collection of pearls and myths. Rheum. Dis. Clin. North Am. 33, 691–739 (2007).
Salvarani, C. et al. Distal musculoskeletal manifestations in polymyalgia rheumatica: a prospective followup study. Arthritis Rheum. 41, 1221–1226 (1998).
Hunder, G. G. The early history of giant cell arteritis and polymyalgia rheumatica: first descriptions to 1970. Mayo Clin. Proc. 81, 1071–1083 (2006).
Gonzalez-Gay, M. A., Garcia-Porrua, C., Amor-Dorado, J. C. & Llorca, J. Giant cell arteritis without clinically evident vascular involvement in a defined population. Arthritis Rheum. 51, 274–277 (2004).
Blockmans, D. et al. Repetitive 18-fluorodeoxyglucose positron emission tomography in isolated polymyalgia rheumatica: a prospective study in 35 patients. Rheumatology (Oxford) 46, 672–677 (2007).
Hernandez-Rodriguez, J. et al. Development of ischemic complications in patients with giant cell arteritis presenting with apparently isolated polymyalgia rheumatica: study of a series of 100 patients. Medicine (Baltimore) 86, 233–241 (2007).
Eshaghian, J. & Goeken, J. A. C-reactive protein in giant cell (cranial, temporal) arteritis. Ophthalmology 87, 1160–1166 (1980).
Salvarani, C., Cantini, F., Boiardi, L. & Hunder, G. G. Laboratory investigations useful in giant cell arteritis and Takayasu's arteritis. Clin. Exp. Rheumatol. 21, S23–S28 (2003).
Kyle, V., Cawston, T. E. & Hazleman, B. L. Erythrocyte sedimentation rate and C reactive protein in the assessment of polymyalgia rheumatica/giant cell arteritis on presentation and during follow up. Ann. Rheum. Dis. 48, 667–671 (1989).
Kyle, V., Wraight, E. P. & Hazleman, B. L. Liver scan abnormalities in polymyalgia rheumatica/giant cell arteritis. Clin. Rheumatol. 10, 294–297 (1991).
Klein, R. G., Campbell, R. J., Hunder, G. G. & Carney, J. A. Skip lesions in temporal arteritis. Mayo Clin. Proc. 51, 504–510 (1976).
Germano, G. et al. Does ultrasonography guidance increase the yield of temporal artery biopsy in patients with giant cell arteritis? Preliminary results from a single-blinded randomized study. Arthritis & Rheumatism 63, S594 (2011).
Salvarani, C. & Hunder, G. G. Giant cell arteritis with low erythrocyte sedimentation rate: frequency of occurence in a population-based study. Arthritis Rheum. 45, 140–145 (2001).
Narvaez, J. et al. Influence of previous corticosteroid therapy on temporal artery biopsy yield in giant cell arteritis. Semin. Arthritis Rheum. 37, 13–19 (2007).
Breuer, G. S., Nesher, G. & Nesher, R. Rate of discordant findings in bilateral temporal artery biopsy to diagnose giant cell arteritis. J. Rheumatol. 36, 794–796 (2009).
Rucker, J. C., Biousse, V. & Newman, N. J. Ischemic optic neuropathies. Curr. Opin. Neurol. 17, 27–35 (2004).
Pipitone, N., Versari, A. & Salvarani, C. Role of imaging studies in the diagnosis and follow-up of large-vessel vasculitis: an update. Rheumatology (Oxford) 47, 403–408 (2008).
Salvarani, C. et al. Is duplex ultrasonography useful for the diagnosis of giant-cell arteritis? Ann. Intern. Med. 137, 232–238 (2002).
Schmidt, W. A., Kraft, H. E., Vorpahl, K., Volker, L. & Gromnica-Ihle, E J. Color duplex ultrasonography in the diagnosis of temporal arteritis. N. Engl. J. Med. 337, 1336–1342 (1997).
Ball, E. L., Walsh, S. R., Tang, T. Y., Gohil, R. & Clarke, J. M. Role of ultrasonography in the diagnosis of temporal arteritis. Br. J. Surg. 97, 1765–1771 (2010).
Arida, A., Kyprianou, M., Kanakis, M. & Sfikakis, P. P. The diagnostic value of ultrasonography-derived edema of the temporal artery wall in giant cell arteritis: a second meta-analysis. BMC Musculoskelet. Disord. 11, 44 (2010).
Bley, T. A. et al. Assessment of the cranial involvement pattern of giant cell arteritis with 3T magnetic resonance imaging. Arthritis Rheum. 52, 2470–2477 (2005).
Walter, M. A. et al. The value of 18FDG-PET in the diagnosis of large-vessel vasculitis and the assessment of activity and extent of disease. Eur. J. Nucl. Med. Mol. Imaging 32, 674–681 (2005).
Blockmans, D. et al. Repetitive 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a prospective study of 35 patients. Arthritis Rheum. 55, 131–137 (2006).
Cantini, F. et al. Shoulder ultrasonography in the diagnosis of polymyalgia rheumatica: a case–control study. J. Rheumatol. 28, 1049–1055 (2001).
Salvarani, C. et al. Proximal bursitis in active polymyalgia rheumatica. Ann. Intern. Med. 127, 27–31 (1997).
Salvarani, C. et al. Cervical interspinous bursitis in active polymyalgia rheumatica. Ann. Rheum. Dis. 67, 758–761 (2008).
Camellino, D. & Cimmino, M. A. Imaging of polymyalgia rheumatica: indications on its pathogenesis, diagnosis and prognosis. Rheumatology (Oxford) 51, 77–86 (2011).
Cantini, F. et al. Inflamed shoulder structures in polymyalgia rheumatica with normal erythrocyte sedimentation rate. Arthritis Rheum. 44, 1155–1159 (2001).
Cantini, F. et al. Fat suppression magnetic resonance imaging in shoulders of patients with polymyalgia rheumatica. J. Rheumatol. 31, 120–124 (2004).
Cimmino, M. A., Parodi, M., Zampogna, G., Barbieri, F. & Garlaschi, G. Polymyalgia rheumatica is associated with extensor tendon tenosynovitis but not with synovitis of the hands: a magnetic resonance imaging study. Rheumatology (Oxford) 50, 494–499 (2011).
Nishino, H., DeRemee, R. A., Rubino, F. A. & Parisi, J. E. Wegener's granulomatosis associated with vasculitis of the temporal artery: report of five cases. Mayo Clin. Proc. 68, 115–121 (1993).
Salvarani, C. et al. Primary systemic amyloidosis presenting as giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum. 37, 1621–1626 (1994).
Genereau, T. et al. Temporal artery biopsy: a diagnostic tool for systemic necrotizing vasculitis. French Vasculitis Study Group. Arthritis Rheum 42, 2674–2681 (1999).
Salvarani, C., Giannini, C., Miller, D. V. & Hunder, G. Giant cell arteritis: Involvement of intracranial arteries. Arthritis Rheum. 55, 985–989 (2006).
Deal, C. L. et al. The clinical features of elderly-onset rheumatoid arthritis. A comparison with younger-onset disease of similar duration. Arthritis & Rheumatism 28, 987–994 (1985).
Lopez-Hoyos, M. et al. Clinical utility of anti-CCP antibodies in the differential diagnosis of elderly-onset rheumatoid arthritis and polymyalgia rheumatica. Rheumatology (Oxford) 43, 655–657 (2004).
Olivieri, I., Salvarani, C. & Cantini, F. Remitting distal extremity swelling with pitting edema: a distinct syndrome or a clinical feature of different inflammatory rheumatic diseases? J. Rheumatol. 24, 249–252 (1997).
Olivieri, I. et al. Late onset undifferentiated spondyloarthritis presenting with polymyalgia rheumatica features: description of seven cases. Rheumatol. Int. 27, 927–933 (2007).
Salvarani, C., Cantini, F., Oliveri, I. & Hunder, G. G. Polymyalgia rheumatica: a disorder of extraarticular synovial structures. J. Rheumatol. 26, 517–521 (1999).
Churchill, M. A., Jr, Geraci, J. E. & Hunder, G. G. Musculoskeletal manifestations of bacterial endocarditis. Ann. Intern. Med 87, 754–759 (1977).
Pipitone, N. & Salvarani, C. Improving therapeutic options for patients with giant cell arteritis. Curr. Opin. Rheumatol. 20, 17–22 (2008).
Sailler, L. et al. Non-complicated Horton's disease: initial treatment with methylprednisolone 500 mg/day bolus for three days followed by 20 mg/day prednisone-equivalent. Evaluation of 15 patients [French]. Rev. Med. Interne 22, 1032–1038 (2001).
Chevalet, P. et al. A randomized, multicenter, controlled trial using intravenous pulses of methylprednisolone in the initial treatment of simple forms of giant cell arteritis: a one year followup study of 164 patients. J. Rheumatol. 27, 1484–1491 (2000).
Hayreh, S. S. & Zimmerman, B. Management of giant cell arteritis. Our 27-year clinical study: new light on old controversies. Ophthalmologica 217, 239–259 (2003).
Kyle, V. & Hazleman, B. L. Treatment of polymyalgia rheumatica and giant cell arteritis. I. Steroid regimens in the first two months. Ann. Rheum. Dis. 48, 658–661 (1989).
Delecoeuillerie, G., Joly, P., Cohen, D. L. & Paolaggi, J. B. Polymyalgia rheumatica and temporal arteritis: a retrospective analysis of prognostic features and different corticosteroid regimens (11 year survey of 210 patients). Ann. Rheum. Dis. 47, 733–739 (1988).
Hunder, G. G., Sheps, S. G., Allen, G. L. & Joyce, J. W. Daily and alternate-day corticosteroid regimens in treatment of giant cell arteritis: comparison in a prospective study. Ann. Intern. Med. 82, 613–618 (1975).
Mukhtyar, C. et al. EULAR recommendations for the management of large vessel vasculitis. Ann. Rheum. Dis. 68, 318–323 (2009).
Mazlumzadeh, M. et al. Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial. Arthritis Rheum. 54, 3310–3318 (2006).
Dasgupta, B. et al. BSR and BHPR guidelines for the management of giant cell arteritis. Rheumatology. (Oxford) 49, 1594–1597 (2010).
Pipitone, N., Boiardi, L. & Salvarani, C. Are steroids alone sufficient for the treatment of giant cell arteritis? Best. Pract. Res. Clin. Rheumatol. 19, 277–292 (2005).
Huston, K. A., Hunder, G. G., Lie, J. T., Kennedy, R. H. & Elveback, L. R. Temporal arteritis: a 25-year epidemiologic, clinical, and pathologic study. Ann. Intern. Med. 88, 162–167 (1978).
Lundberg, I. & Hedfors, E. Restricted dose and duration of corticosteroid treatment in patients with polymyalgia rheumatica and temporal arteritis. J. Rheumatol. 17, 1340–1345 (1990).
Graham, E., Holland, A., Avery, A. & Russell, R. W. Prognosis in giant-cell arteritis. Br. Med. J. (Clin. Res. Ed) 282, 269–271 (1981).
Hayreh, S. S. & Zimmerman, B. Visual deterioration in giant cell arteritis patients while on high doses of corticosteroid therapy. Ophthalmology 110, 1204–1215 (2003).
Ostor, A. J. & Hazleman, B. L. Polymyalgia rheumatica and giant-cell arteritis. N. Engl. J. Med. 347, 2083–2085 (2002).
Kyle, V. & Hazelman, B. L. Stopping steroids in polymyalgia rheumatica and giant cell arteritis. BMJ 300, 344–345 (1990).
Dasgupta, B. et al. BSR and BHPR guidelines for the management of polymyalgia rheumatica. Rheumatology (Oxford) 49, 186–190 (2010).
Proven, A., Gabriel, S. E., Orces, C., O'Fallon, W. M. & Hunder, G. G. Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum. 49, 703–708 (2003).
Gabriel, S. E., Sunku, J., Salvarani, C., O'Fallon, W. M. & Hunder, G. G. Adverse outcomes of antiinflammatory therapy among patients with polymyalgia rheumatica. Arthritis Rheum. 40, 1873–1878 (1997).
De Silva, M. & Hazleman, B. L. Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study. Ann. Rheum. Dis. 45, 136–138 (1986).
Spiera, R. F. et al. A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA). Clin. Exp. Rheumatol. 19, 495–501 (2001).
Jover, J. A. et al. Combined treatment of giant-cell arteritis with methotrexate and prednisone. a randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 134, 106–114 (2001).
Hoffman, G. S. et al. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum. 46, 1309–1318 (2002).
Mahr, A. D. et al. Adjunctive methotrexate to treat giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum. 56, 2789–2797 (2007).
van der Veen, M. J., Dinant, H. J., Booma-Frankfort, C., Albada-Kuipers, G. A. & Bijlsma, J. W. Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis? Ann. Rheum. Dis. 55, 218–223 (1996).
Caporali, R. et al. Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 141, 493–500 (2004).
Hoffman, G. S. et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann. Intern. Med. 146, 621–630 (2007).
Salvarani, C. et al. Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica: a randomized trial. Ann. Intern. Med. 146, 631–639 (2007).
Kreiner, F. & Galbo, H. Effect of etanercept in polymyalgia rheumatica: a randomized controlled trial. Arthritis Res. Ther. 12, R176 (2010).
Martinez-Taboada, V. M. et al. A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Ann. Rheum. Dis. 67, 625–630 (2008).
Salvarani, C. et al. Treatment of refractory polymyalgia rheumatica with infliximab: a pilot study. J. Rheumatol. 30, 760–763 (2003).
Cantini, F., Niccoli, L., Salvarani, C., Padula, A. & Olivieri, I. Treatment of longstanding active giant cell arteritis with infliximab: report of four cases. Arthritis Rheum. 44, 2933–2935 (2001).
Watson, P. & Gaston, H. Response to 'Effect of etanercept in polymyalgia rheumatica: a randomized controlled trial'. Arthritis Res. Ther. 13, 403 (2011).
Seitz, M. et al. Rapid induction of remission in large vessel vasculitis by IL-6 blockade. A case series. Swiss. Med. Wkly 141, w13156 (2011).
Salvarani, C. et al. Tocilizumab: a novel therapy for patients with large-vessel vasculitis. Rheumatology (Oxford) 51, 151–156 (2012).
Hagihara, K., Kawase, I., Tanaka, T. & Kishimoto, T. Tocilizumab ameliorates clinical symptoms in polymyalgia rheumatica. J. Rheumatol. 37, 1075–1076 (2010).
Nesher, G. et al. Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. Arthritis Rheum. 50, 1332–1337 (2004).
Lee, M. S., Smith, S. D., Galor, A. & Hoffman, G. S. Antiplatelet and anticoagulant therapy in patients with giant cell arteritis. Arthritis Rheum. 54, 3306–3309 (2006).
Narvaez, J. et al. Impact of antiplatelet therapy in the development of severe ischemic complications and in the outcome of patients with giant cell arteritis. Clin. Exp. Rheumatol. 26, S57–S62 (2008).
Leeb, B. F. et al. EULAR response criteria for polymyalgia rheumatica: results of an initiative of the European Collaborating Polymyalgia Rheumatica Group (subcommittee of ESCISIT). Ann. Rheum. Dis. 62, 1189–1194 (2003).
Leeb, B. F. & Bird, H. A. A disease activity score for polymyalgia rheumatica. Ann. Rheum Dis. 63, 1279–1283 (2004).
Matteson, E. L. et al. Patient-reported outcomes in polymyalgia rheumatica. J. Rheumatol. 39, 795–803 (2012).
Chuang, T. Y., Hunder, G. G., Ilstrup, D. M. & Kurland, L. T. Polymyalgia rheumatica: a 10-year epidemiologic and clinical study. Ann. Intern. Med. 97, 672–680 (1982).
Healey, L. A. Long-term follow-up of polymyalgia rheumatica: evidence for synovitis. Semin. Arthritis Rheum. 13, 322–328 (1984).
Bird, H. A., Esselinckx, W., Dixon, A. S., Mowat, A. G. & Wood, P. H. An evaluation of criteria for polymyalgia rheumatica. Ann. Rheum. Dis. 38, 434–439 (1979).
Michet, C. J. & Matteson, E. L. Polymyalgia rheumatica. BMJ 336, 765–769 (2008).
Author information
Authors and Affiliations
Contributions
C. Salvarani and N. Pipitone researched data for the article. C. Salvarani, N. Pipitone and A. Versari made equal contributions to discussion of content. N. Pipitone wrote the article. All authors contributed equally to reviewing and editing the manuscript before submission.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Salvarani, C., Pipitone, N., Versari, A. et al. Clinical features of polymyalgia rheumatica and giant cell arteritis. Nat Rev Rheumatol 8, 509–521 (2012). https://doi.org/10.1038/nrrheum.2012.97
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2012.97
This article is cited by
-
Glucocorticoid discontinuation rate and risk factors for relapses in a contemporary cohort of patients with giant cell arteritis
Rheumatology International (2024)
-
Tongue necrosis secondary to giant cell arteritis, successfully treated with tocilizumab: a case report
BMC Musculoskeletal Disorders (2023)
-
Vision loss in giant cell arteritis: case-based review
Rheumatology International (2022)
-
Giant Cell Arteritis: A Case-Based Narrative Review of the Literature
Current Pain and Headache Reports (2022)
-
Patient Reported Outcomes in Large Vessel Vasculitides
Current Rheumatology Reports (2021)